Researcher

Tjan - Heijnen, V.C.G.

Full professor - Key domain chair, H/MS

View graph of relations
  1. 2019
  2. Published
  3. Published
  4. Published
    Angus, L., Smid, M., Wilting, S. M., van Riet, J., Van Hoeck, A., Luan Nguyen, ... Martens, J. W. M. (2019). The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nature Genetics, 51(10), 1450-1458. https://doi.org/10.1038/s41588-019-0507-7
  5. Published
  6. Published
  7. Published
  8. Published
  9. Published
  10. Published
  11. Published
  12. Published
  13. Published
    Lameijer, J. R. C., Coolen, A. M. P., Voogd, A. C., Strobbe, L. J., Louwman, M. W. J., Venderink, D., ... Duijm, L. E. M. (2019). Correction to: Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. European Radiology, 29(2), 1059-1059. https://doi.org/10.1007/s00330-018-5532-x
  14. Published
  15. Published
  16. Published
  17. 2018
  18. Published
  19. Published
    Thijssen, V. L. J. L., Paulis, Y. W. J., Nowak-Sliwinska, P., Deumelandt, K. L., Hosaka, K., Soetekouw, P. M. M. B., ... Griffioen, A. W. (2018). Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. Journal of Pathology, 246(4), 447-458. https://doi.org/10.1002/path.5152
  20. Published
  21. Published
    Dutch Breast Canc Res Grp BOOG, Claessens, A. K. M., Bos, M. E. M. M., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., ... Erdkamp, F. L. G. (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment, 172(2), 413-423. https://doi.org/10.1007/s10549-018-4906-8
  22. Published
  23. Published
    Lameijer, J. R. C., Coolen, A. M. P., Voogd, A. C., Strobbe, L. J., Louwman, M. W. J., Venderink, D., ... Duijm, L. E. M. (2018). Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. European Radiology, 28(10), 4205-4214. https://doi.org/10.1007/s00330-018-5370-x
  24. Published
  25. Published
  26. Published
  27. Published
  28. Published
  29. Published
  30. Published
  31. Published
    van Bommel, R. M. G., Voogd, A. C., Nederend, J., Setz-Pels, W., Louwman, M. W. J., Strobbe, L. J., ... Duijm, L. E. M. (2018). Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. Breast, 38, 101-106. https://doi.org/10.1016/j.breast.2017.12.018
  32. Published
  33. Published
  34. Published
  35. Published
  36. Published
  37. Published
  38. 2017
  39. Published
  40. Published
  41. Published
    Tjan-Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., ... Dutch Breast Canc Res Grp B (2017). Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet oncology, 18(11), 1502-1511. https://doi.org/10.1016/S1470-2045(17)30600-9
  42. Published
  43. Published
  44. Published
  45. Published
  46. Published
  47. Published
  48. Published
    von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., ... Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 377(2), 122-131. https://doi.org/10.1056/NEJMoa1703643
  49. Published
  50. Published
  51. Published
  52. Published
  53. Published
Previous 1 2 3 Next